Riskpilot← Back to searchSign inGet full accessUROKLINIKKEN AS
ASActiveOrg 922303320Veitvetveien 8, 0596 OsloMedical specialists activities · NACE 8622Est. 20195 employees
Revenue 2024
NOK 5,3M
+2% vs 2023
EBITDA margin
-2.5%
-111% vs 2023
Equity ratio
79.6%
Financial strength
Net profit 2024
NOK -633K
-221% vs 2023
| Revenue | NOK 5,3M | +2% |
| EBITDA | NOK -130K | -111% |
| Net profit | NOK -633K | -221% |
| Total assets | NOK 1,7M | -43% |
| Equity | NOK 1,3M | -32% |
| Employees | 5 | — |
Legal name
UROKLINIKKEN AS
Org number
922303320
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
7. mars 2019
Share capital
NOK 30 000
Employees
5 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Lege innen urologi. Distribuering av medisinutstyr. Kjøp og salg av eiendom.
Address
Veitvetveien 8, 0596 Oslo
Phone
+4792097980
Email
uroklinikken@post.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 5 413 | 4 646 | 5 881 | 5 145 | 5 265 |
| Staff expenses | −3 179 | −2 504 | −1 463 | −1 271 | −2 453 |
| EBITDA | 601 | 239 | 2 945 | 1 166 | −130 |
| Depreciation & amort. | −73 | −83 | −249 | −412 | −420 |
| EBIT | 528 | 156 | 2 697 | 754 | −550 |
| Net financials | −10 | −4 | −18 | −73 | −90 |
| Profit before tax | 518 | 152 | 2 678 | 681 | −640 |
| Tax | 112 | 33 | 752 | 159 | −7 |
| Net profit | 406 | 119 | 1 927 | 522 | −633 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 938 | 1 743 | 2 113 | 2 900 | 1 661 |
| Equity | 35 | 154 | 1 433 | 1 955 | 1 322 |
| Long-term debt | 189 | 882 | 1 312 | 1 155 | 988 |
| Short-term debt | 714 | 708 | −632 | −210 | −649 |
| Total debt | 903 | 1 589 | 680 | 945 | 339 |
EBITDA margin
-2.5%
This company
15.8%
Market median
-116% vs market
20202024
Equity ratio
79.6%
This company
38.2%
Market median
+108% vs market
20202024
Return on equity
-47.9%
This company
18.4%
Market median
-360% vs market
20202024
Net profit margin
-12.0%
This company
8.1%
Market median
-248% vs market
20202024
Asset turnover
3.17×
This company
1.12×
Market median
+183% vs market
20202024
Debt / equity
0.26×
This company
0.62×
Market median
+58% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
RZ Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2019 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Zare Holding As
UROKLINIKKEN AS Board members of UROKLINIKKEN AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ramin Zare | Chief Executive Officer | 0 companies |
| Reza Zare | Chairman | 0 companies |